Co-Target(s) Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T76685 | Target Info | |||
Target Name | Cannabinoid receptor 1 (CB1) | ||||
Synonyms |
Cannabinoid CB1 receptor; CNR; CB-R; CANN6
Click to Show/Hide
|
||||
Target Type | Successful Target | ||||
Gene Name | CNR1 | ||||
Biochemical Class | GPCR rhodopsin | ||||
UniProt ID |
Co-Targets of This Target | Top | |||||
---|---|---|---|---|---|---|
Co-Target Name | Pancreatic triacylglycerol lipase (PNLIP) | Successful Target | ||||
UniProt ID | LIPP_HUMAN | |||||
Gene Name | PNLIP | |||||
Synonyms |
Pancreatic lipase; PTL; PL
Click to Show/Hide
|
|||||
Representative Drug(s) | Orlistat | Drug Info | IC50 = 0.04 ug.mL-1 | [1] | ||
Co-Target Name | Cannabinoid receptor 2 (CB2) | Successful Target | ||||
UniProt ID | CNR2_HUMAN | |||||
Gene Name | CNR2 | |||||
Synonyms |
hCB2; Cannabinoid CB2 receptor; CX5; CB2B; CB2A; CB-2
Click to Show/Hide
|
|||||
Representative Drug(s) | SR141716A | Drug Info | Ki = 1.1 nM | Click to Show More | [2] | |
2 | Marinol | Drug Info | EC50 = 1.5 nM | [3] | ||
3 | NABILONE | Drug Info | Ki = 1.84 nM | [4] | ||
4 | SR-147778 | Drug Info | Ki = 442 nM | [9] | ||
Co-Target Name | S-mephenytoin 4-hydroxylase (CYP2C9) | Successful Target | ||||
UniProt ID | CP2C9_HUMAN | |||||
Gene Name | CYP2C9 | |||||
Synonyms |
Cytochrome P450 PB-1; Cytochrome P450 MP-8; Cytochrome P450 MP-4; Cytochrome P450 2C9; Cytochrome P-450MP; Cholesterol 25-hydroxylase; CYPIIC9; CYP2C10; (S)-limonene 7-monooxygenase; (S)-limonene 6-monooxygenase; (R)-limonene 6-monooxygenase
Click to Show/Hide
|
|||||
Representative Drug(s) | SR141716A | Drug Info | IC50 = 5.3 nM | [5] | ||
Co-Target Name | Dopamine D3 receptor (D3R) | Successful Target | ||||
UniProt ID | DRD3_HUMAN | |||||
Gene Name | DRD3 | |||||
Synonyms |
D(3) dopamine receptor
Click to Show/Hide
|
|||||
Representative Drug(s) | Marinol | Drug Info | EC50 = 10.2 nM | [6] | ||
Co-Target Name | Debrisoquine 4-hydroxylase (CYP2D6) | Successful Target | ||||
UniProt ID | CP2D6_HUMAN | |||||
Gene Name | CYP2D6 | |||||
Synonyms |
P450-DB1; Cytochrome P450-DB1; Cytochrome P450 2D6; CYPIID6; CYP2DL1
Click to Show/Hide
|
|||||
Representative Drug(s) | SR141716A | Drug Info | IC50 ~ 20 nM | [5] | ||
Co-Target Name | Lipoprotein lipase (LPL) | Successful Target | ||||
UniProt ID | LIPL_HUMAN | |||||
Gene Name | LPL | |||||
Synonyms |
LIPD
Click to Show/Hide
|
|||||
Representative Drug(s) | Orlistat | Drug Info | IC50 = 66 nM | [7] | ||
Co-Target Name | Fatty acid synthase (FASN) | Successful Target | ||||
UniProt ID | FAS_HUMAN | |||||
Gene Name | FASN | |||||
Synonyms |
Yeast fatty acid synthase; Fatty-acyl-CoA synthase; Fatty acyl-CoA synthetase enzyme; FAS
Click to Show/Hide
|
|||||
Representative Drug(s) | Orlistat | Drug Info | Ki = 280 nM | [8] | ||
Co-Target Name | Endothelial lipase (LIPG) | Clinical trial Target | ||||
UniProt ID | LIPE_HUMAN | |||||
Gene Name | LIPG | |||||
Synonyms |
Endothelial cell-derived lipase; EL; EDL
Click to Show/Hide
|
|||||
Representative Drug(s) | Orlistat | Drug Info | IC50 = 6 nM | [7] | ||
Co-Target Name | Albendazole monooxygenase (CYP3A4) | Clinical trial Target | ||||
UniProt ID | CP3A4_HUMAN | |||||
Gene Name | CYP3A4 | |||||
Synonyms |
Taurochenodeoxycholate 6-alpha-hydroxylase; Quinine 3-monooxygenase; P450-PCN1; Nifedipine oxidase; NF-25; HLp; Cytochrome P450-PCN1; Cytochrome P450 NF-25; Cytochrome P450 HLp; Cytochrome P450 3A4; Cytochrome P450 3A3; CYPIIIA4; CYPIIIA3; CYP3A3; Albendazole sulfoxidase; Albendazole monooxygenase (sulfoxide-forming); 1,8-cineole 2-exo-monooxygenase
Click to Show/Hide
|
|||||
Representative Drug(s) | SR141716A | Drug Info | IC50 ~ 20 nM | [5] | ||
Co-Target Name | Platelet-activating factor acetylhydrolase (PLA2G7) | Clinical trial Target | ||||
UniProt ID | PAFA_HUMAN | |||||
Gene Name | PLA2G7 | |||||
Synonyms |
gVIIA-PLA2; PAFAH; PAF acetylhydrolase; PAF 2-acylhydrolase; Lipoprotein-associated phospholipase A2; LDL-associated phospholipase A2; LDL-PLA(2); Group-VIIA phospholipase A2; 2-acetyl-1-alkylglycerophosphocholine esterase; 1-alkyl-2-acetylglycerophosphocholine esterase
Click to Show/Hide
|
|||||
Representative Drug(s) | Orlistat | Drug Info | IC50 = 50 nM | [10] | ||
Co-Target Name | Diacylglycerol lipase alpha (DAGLA) | Patented-recorded Target | ||||
UniProt ID | DGLA_HUMAN | |||||
Gene Name | DAGLA | |||||
Synonyms |
Sn1-specific diacylglycerol lipase alpha; Neural stem cell-derived dendrite regulator; NSDDR; KIAA0659; DGL-alpha; C11orf11
Click to Show/Hide
|
|||||
Representative Drug(s) | Orlistat | Drug Info | IC50 = 1 nM | [11] | ||
Co-Target Name | Monoacylglycerol lipase ABHD6 (ABHD6) | Patented-recorded Target | ||||
UniProt ID | ABHD6_HUMAN | |||||
Gene Name | ABHD6 | |||||
Synonyms |
Abhydrolase domain-containing protein 6; 2-arachidonoylglycerol hydrolase
Click to Show/Hide
|
|||||
Representative Drug(s) | Orlistat | Drug Info | IC50 = 13.18 nM | [12] | ||
Co-Target Name | Diacylglycerol lipase beta (DAGLB) | Literature-reported Target | ||||
UniProt ID | DGLB_HUMAN | |||||
Gene Name | DAGLB | |||||
Synonyms |
Sn1-specific diacylglycerol lipase beta; KCCR13L; DGL-beta
Click to Show/Hide
|
|||||
Representative Drug(s) | Orlistat | Drug Info | IC50 = 60 nM | [10] | ||
Co-Target Name | N-arachidonyl glycine receptor (GPR18) | Literature-reported Target | ||||
UniProt ID | GPR18_HUMAN | |||||
Gene Name | GPR18 | |||||
Synonyms |
NAGly receptor; GPCRW; G-protein coupled receptor 18
Click to Show/Hide
|
|||||
Representative Drug(s) | Marinol | Drug Info | EC50 = 960 nM | [13] | ||
Co-Target Name | Hepatic lipase (LIPC) | Co-Target | ||||
UniProt ID | LIPC_HUMAN | |||||
Gene Name | LIPC | |||||
Synonyms |
Hepatic triacylglycerol lipase; HL; Lipase member C; Lysophospholipase; Phospholipase A1
Click to Show/Hide
|
|||||
Representative Drug(s) | Orlistat | Drug Info | IC50 = 3 nM | [7] | ||
Co-Target Name | Cytochrome P450 1A2 (CYP1A2) | Co-Target | ||||
UniProt ID | CP1A2_HUMAN | |||||
Gene Name | CYP1A2 | |||||
Synonyms |
Cholesterol 25-hydroxylase; Hydroperoxy icosatetraenoate dehydratase; CYPIA2; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3
Click to Show/Hide
|
|||||
Representative Drug(s) | SR141716A | Drug Info | IC50 ~ 20 nM | [5] | ||
Co-Target Name | Phosphatidylserine lipase ABHD16A (ABHD16A) | Co-Target | ||||
UniProt ID | ABHGA_HUMAN | |||||
Gene Name | ABHD16A | |||||
Synonyms |
Alpha/beta hydrolase domain-containing protein 16A; Abhydrolase domain-containing protein 16A; HLA-B-associated transcript 5; hBAT5; Monoacylglycerol lipase ABHD16A; Protein G5
Click to Show/Hide
|
|||||
Representative Drug(s) | Orlistat | Drug Info | IC50 = 30 nM | [10] | ||
Co-Target Name | Monoacylglycerol lipase ABHD12 (ABHD12) | Co-Target | ||||
UniProt ID | ABD12_HUMAN | |||||
Gene Name | ABHD12 | |||||
Synonyms |
Lysophosphatidylserine lipase ABHD12; 2-arachidonoylglycerol hydrolase ABHD12; Abhydrolase domain-containing protein 12; hABHD12; Oxidized phosphatidylserine lipase ABHD12
Click to Show/Hide
|
|||||
Representative Drug(s) | Orlistat | Drug Info | IC50 = 80 nM | [10] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Biologically active triterpenoid saponins from Acanthopanax senticosus. J Nat Prod. 2006 Nov;69(11):1577-81. | ||||
REF 2 | Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity. Bioorg Med Chem. 2014 Jul 1;22(13):3245-51. | ||||
REF 3 | Novel benzimidazole derivatives as selective CB2 agonists. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3695-700. | ||||
REF 4 | Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. J Med Chem. 2013 Nov 14;56(21):8224-56. | ||||
REF 5 | Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist. Bioorg Med Chem. 2010 Sep 1;18(17):6377-88. | ||||
REF 6 | Design, Synthesis, Structure-Activity Relationship Studies, and Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) Modeling of a Series of O-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolase. J Med Chem. 2017 Mar 23;60(6):2287-304. | ||||
REF 7 | Sulfonylated Benzothiazoles as Inhibitors of Endothelial Lipase. ACS Med Chem Lett. 2018 Nov 21;9(12):1263-1268. | ||||
REF 8 | The lipogenesis pathway as a cancer target. J Med Chem. 2011 Aug 25;54(16):5615-38. | ||||
REF 9 | The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem. 2005 Aug 11;48(16):5059-87. | ||||
REF 10 | Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5838-41. | ||||
REF 11 | Structure activity relationship studies on chemically non-reactive glycine sulfonamide inhibitors of diacylglycerol lipase. Bioorg Med Chem. 2016 Apr 1;24(7):1455-68. | ||||
REF 12 | Revisiting 1,3,4-Oxadiazol-2-ones: Utilization in the Development of ABHD6 Inhibitors. Bioorg Med Chem. 2015 Oct 1;23(19):6335-45. | ||||
REF 13 | Bicyclic imidazole-4-one derivatives: a new class of antagonists for the orphan G protein-coupled receptors GPR18 and GPR55. Medchemcomm. 2014;5:632-49. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.